Creatine and Type 2 Diabetes: What the Glucose Metabolism and Insulin Sensitivity Research Shows

Diabetes affects roughly 38 million people in the United States, with type 2 diabetes accounting for the large majority of cases, and it is characterized by progressive insulin resistance and impaired glucose metabolism [1]. Exercise and dietary modification remain first-line interventions. Researchers have asked whether strategies that improve cellular energy status add anything measurable on top of them, and creatine monohydrate, traditionally studied for athletic performance, has become one such research candidate in glucose metabolism.

Skeletal muscle is the predominant site of insulin-mediated glucose uptake, and muscle insulin resistance is considered an early and central defect in type 2 diabetes [2]. Because glucose transport and glycogen synthesis are energy-dependent, the rationale for studying creatine centers on the creatine kinase/phosphocreatine system, which regenerates ATP and shuttles energy within the cell [3]. Reviews of this literature propose that raising muscle creatine and phosphocreatine might support the energetic and signaling steps involved in glucose uptake, while emphasizing that the human evidence base is small and mixed [4]. This article summarizes what the published studies actually measured, and where the evidence stops.

What is Creatine?

Creatine is an endogenous compound synthesized mainly in the liver, kidneys and pancreas from the amino acids glycine, arginine and methionine, and roughly 95% of the body's creatine is stored in skeletal muscle as free creatine and phosphocreatine [5]. Dietary sources include red meat and fish, although the intakes used in research are generally higher than diet alone provides [5].

Phosphocreatine acts as an immediately available temporal energy buffer. The creatine kinase reaction transfers a phosphate group from phosphocreatine to ADP to regenerate ATP much faster than glycolysis or oxidative phosphorylation can, and the same system functions as an intracellular energy shuttle between sites of ATP production and ATP use [3]. Whether this buffering capacity meaningfully influences insulin signaling in metabolic disease is the open question the clinical studies below address.

Creatine monohydrate, the most studied form, consists of one creatine molecule bound to one water molecule. The quickest way to raise muscle creatine stores is about 0.3 g/kg/day (roughly 20 g/day) for 5-7 days followed by 3-5 g/day to maintain them; ingesting 3-5 g/day from the outset also raises stores, over roughly 3-4 weeks [5]. People starting from lower baseline stores, such as those with low dietary creatine intake, tend to show the larger relative increases [5].

What is Creatine Used For in Metabolic Research?

In the context of glucose metabolism and type 2 diabetes, creatine supplementation has been investigated for several distinct but interrelated outcomes:

• Insulin sensitivity measures: Studies examine whether creatine changes the cellular response to insulin, most often using HOMA-IR or insulin and C-peptide responses during glucose or meal tolerance tests rather than hyperinsulinemic-euglycemic clamps [6].
• Glycemic control markers: Research quantifies effects on fasting glucose, glucose excursions during tolerance testing, and hemoglobin A1c [6].
• Glucose transporter function: Mechanistic work assesses GLUT-4 protein content and GLUT-4 translocation to the cell membrane, a key step in insulin-stimulated glucose uptake [4].
• Exercise-independent effects: A few trials give creatine without a training program in order to separate any direct metabolic effect from exercise-mediated improvements in glucose disposal [6].
• Combination with exercise training: Most of the positive human data come from protocols in which creatine was added to a supervised training program, so training is a co-intervention rather than a background variable [4].

Evidence and Mechanisms

The most-cited early study, by Gualano and colleagues (2008), randomized 22 sedentary healthy men to creatine or placebo (dextrose) for three months, with all participants performing moderate-intensity aerobic training. The creatine group showed a significantly greater reduction in the glucose area under the curve during an oral glucose tolerance test than placebo, with no differences in fasting insulin or HOMA-IR [7]. This was a three-month supplementation-plus-training protocol (approximately 20 g/day for the first week, then approximately 10 g/day), not an acute loading study before a single glucose challenge, so its result cannot be separated from the training stimulus.

The same group's 2011 trial extended the question to type 2 diabetes. Twenty-five patients (creatine n = 13, placebo n = 12) received creatine 5 g/day or placebo for 12 weeks while enrolled in an exercise training program. HbA1c fell in the creatine group (7.4 +/- 0.7% before, 6.4 +/- 0.4% after) but not with placebo (7.5 +/- 0.6% before, 7.6 +/- 0.7% after; p = 0.004; between-group difference -1.1%, 95% CI -1.9 to -0.4). The creatine group also showed a lower delta area under the glucose curve, lower glycemia at 0, 30 and 60 minutes of a meal tolerance test, and increased GLUT-4 translocation, while insulin and C-peptide concentrations, physical capacity, lipid profile and adverse effects were comparable between groups [8]. Importantly, total GLUT-4 content did not increase; only translocation did [6].

In this 12-week trial in 25 patients, HbA1c fell from 7.4% to 6.4% with creatine plus exercise and was unchanged with placebo, a between-group difference of 1.1 percentage points (95% CI -1.9 to -0.4) [8].

Mechanistic work is limited and partly discordant. An ancillary analysis of that same cohort (n = 10) found AMPK-alpha protein content tended to be higher after 5 g/day for 12 weeks (p = 0.06), and that changes in AMPK-alpha correlated with changes in GLUT-4 translocation (r = 0.78) and with HbA1c (r = -0.68), suggesting AMPK signaling may be implicated [9]. In L6 rat skeletal muscle cells, 48 hours of creatine raised cellular creatine and phosphocreatine approximately 9.3-fold and 5.1-fold, increased glucose oxidation and AMPK phosphorylation and reduced lactate production, but did not alter glycogen or GLUT4 content, nor the insulin-stimulated rates of 2-deoxyglucose uptake, GLUT4 translocation, glycogen synthesis or glucose oxidation [10]. In other words, the cell-culture data support an AMPK and substrate-oxidation effect, not an increase in insulin-stimulated glucose uptake. The interaction between creatine, insulin, and glucose uptake runs in both directions in the literature: insulin and carbohydrate co-ingestion increase creatine retention in muscle [5], while creatine's effect on glucose disposal in humans remains unsettled.

Pooled evidence does not currently show a consistent effect. A systematic review and meta-analysis searching the literature to December 2020 included nine studies, five of which reported benefit on at least one diabetes-related parameter; the pooled analysis found no significant effect on fasting blood glucose (SMD 0.05; 95% CI -0.53 to 0.63) and no significant effect on insulin resistance (SMD -0.38; 95% CI -0.90 to 0.14) [11].

Not all studies report positive findings. In healthy, untrained men given creatine without a training program, 20 g/day for 5 days followed by 3 g/day for 28 days did not alter insulin action [12]. In chow-fed rats, 8 weeks of creatine feeding raised the peak insulin response to a glucose challenge and fasting insulin, and peak plasma glucose was higher in the supplemented animals, a direction opposite to the human trials [13]; animal findings should not be extrapolated to people. Taken together, the human improvements reported so far have occurred when creatine was combined with exercise training, which is why training is best regarded as part of the intervention rather than background [6][11].

Clinical Considerations

People With Type 2 Diabetes

Creatine is not a treatment for type 2 diabetes and does not replace prescribed therapy. The randomized glycemic evidence in this population is essentially one small 12-week trial of 25 patients, in which every participant also trained [8]. Key considerations:

• The reported effect comes from a single small trial (between-group HbA1c difference -1.1%, 95% CI -1.9 to -0.4) and has not been replicated; pooled analyses across studies are null for fasting glucose and insulin resistance [8][11].
• In a companion analysis of the same trial, creatine 5 g/day for 12 weeks did not impair kidney function in type 2 diabetic patients with normal baseline renal function [14]. People with existing kidney disease were not studied.
• Creatine supplementation can raise serum creatinine without indicating kidney injury, which may complicate interpretation of creatinine-based estimates of kidney function; clinicians should be told about supplement use before labs are interpreted [5].
• Any change in glucose readings should be discussed with the prescribing clinician, particularly for people using insulin or insulin secretagogues, and glucose monitoring should continue as usual.
• Trials that gave creatine without a training program have not shown changes in insulin action, so exercise appears to be part of the intervention rather than an optional add-on [12].

Prediabetes and Metabolic Syndrome

No randomized trial has tested whether creatine affects progression from impaired fasting glucose or metabolic syndrome to type 2 diabetes, and systematic reviews of this literature identify no prevention data [6][11]. Statements that creatine delays progression to diabetes are not supported by the published evidence. What can be said is that the trials conducted to date have been short (mostly 4 to 12 weeks) and small, and prevention trials are lacking.

Sedentary and Overweight Populations

Evidence in sedentary individuals who are not training is limited and negative so far: 5 days of loading followed by 28 days of 3 g/day did not alter insulin action in healthy untrained men [12]. The often-cited 2008 study in sedentary healthy males is sometimes described as an exercise-independent result, but participants in that trial performed three months of moderate-intensity aerobic training alongside supplementation [7]. For people who are not exercising, the honest summary is that meaningful metabolic change from creatine alone has not been demonstrated.

Medication Considerations

No clinically established pharmacokinetic interactions between creatine and common diabetes medications have been reported, but formal interaction studies are essentially absent, so this reflects an absence of data rather than demonstrated safety in every combination. Concern that improved insulin sensitivity could potentiate glucose-lowering drugs remains theoretical, since pooled human data show no significant effect on fasting glucose or insulin resistance [11]. AMPK signaling has been proposed as a shared pathway with metformin on the basis of correlational and cell-culture data [9][10], but no trial has tested creatine plus metformin, and no data exist for creatine combined with SGLT2 inhibitors or GLP-1 receptor agonists.

Dosing Protocols in Metabolic Studies

The type 2 diabetes trial used maintenance dosing of 5 g/day for 12 weeks with no loading phase [8]. Loading protocols (20 g/day for 5 days, then 3 g/day) were used in shorter glucose-tolerance studies, which reported no change in insulin action [12]; the general loading-and-maintenance scheme is described in the International Society of Sports Nutrition position stand [5]. Evidence on timing relative to meals for metabolic outcomes is lacking, unlike performance applications where timing may influence response.

How to Choose Creatine for Metabolic Research Applications

• Select creatine monohydrate: It is the most extensively studied form and the one used in the glucose-metabolism trials discussed above [5][8]. Alternative forms such as HCl and ethyl ester have not been tested in diabetes populations and have no demonstrated advantage for glucose metabolism.
• Micronization is a practical, not a clinical, feature: Micronized powder is marketed as dissolving more readily, which can make daily dosing easier; it has not been shown to change metabolic outcomes.
• Confirm third-party testing: Independent testing for purity and banned substances reduces the risk of undisclosed or contaminant ingredients, a general quality consideration for any supplement.
• Avoid proprietary blends: Studies use isolated creatine monohydrate. Products combining creatine with stimulants or undisclosed ingredients introduce variables that no trial has evaluated, which is particularly relevant for people managing blood glucose.
• Check for added carbohydrates: Some formulations add dextrose because carbohydrate and insulin increase creatine retention in muscle [5]. People managing blood glucose may prefer unflavored, carbohydrate-free creatine monohydrate and should account for any added carbohydrate in their overall plan.

Conclusion

The research on creatine and glucose metabolism is best described as early and mixed rather than established. One small 12-week randomized trial in 25 people with type 2 diabetes who were also exercise training reported a 1.1 percentage-point HbA1c difference versus placebo along with increased GLUT-4 translocation [8], and an ancillary analysis linked those changes to AMPK-alpha protein content [9]. A three-month trial in sedentary healthy men undergoing aerobic training reported a lower glucose area under the curve without changes in fasting insulin or HOMA-IR [7]. Against that, a systematic review and meta-analysis of nine studies found no significant pooled effect on fasting blood glucose or insulin resistance [11], a controlled study in untrained men found no change in insulin action without training [12], and cell-culture work found no increase in insulin-stimulated glucose uptake or GLUT4 translocation [10].

Creatine is not a treatment for type 2 diabetes, is not a substitute for prescribed medication, and should not be expected to substitute for exercise or dietary change. What the evidence supports is narrower: in the trials that reported glycemic benefit, creatine was added to a supervised training program, the samples were small, and the findings have not been replicated or confirmed in pooled analyses. For people already resistance or aerobic training, creatine monohydrate is a well-characterized supplement with a good safety record in short-term trials, including one showing no impairment of kidney function in type 2 diabetic patients with normal baseline renal function [14]. Anyone managing diabetes should discuss supplementation with their healthcare provider and continue routine glucose monitoring.